Combination of zerumbone and cisplatin to treat cervical intraepithelial neoplasia in female BALB/c mice

International Journal of Gynecological Cancer

Volumn 19, Issue 6, 2009, Pages 1004-1010

  Abdul, Ahmad Bustamam ^a   Abdelwahab, Siddig Ibrahim ^a   Jalinas, Johari Bin ^a   Al Zubairi, Adel Sharaf ^a   Taha, Manal Mohamed Elhassan ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Cervical intraepithelial neoplasia; Cisplatin; Synergy; Zerumbone

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; CISPLATIN; EOSIN; HEMATOXYLIN; INTERLEUKIN 6; ISOTONIC SOLUTION; SODIUM CHLORIDE; TETRAZOLIUM; UNCLASSIFIED DRUG; ZERUMBONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MOUSE; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; STAINING; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELL SURVIVAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CISPLATIN; DIETHYLSTILBESTROL; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; SESQUITERPENES; UTERINE CERVICAL NEOPLASMS;

EID: 70349229316     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a83b51     Document Type: Article

References (32)

1. Naghizadeh B, Boroushaki MT, Vahdati Mashhadian N, et al. Protective effects of crocin against cisplatin-induced acute renal failure and oxidative stress in rats. Iran Biomed J. 2008;12:93-100.
2. Keskar V, Mohanty PS, Gemeinhart EJ, et al. Cervical cancer treatment with a locally insertable controlled release delivery system. J Control Release. 2006;115:280-288.
3. Tfayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol. 1999;42:73-77.
4. Zicca A, Cafaggi S, Mariggiò MA, et al. Eur J Pharmacol. 2002;442: 265-272.
5. Chung WH, Boo SH, Chung MK, et al. Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol. 2008;12:1-8.
6. Tanaka T, Shimizu M, Kohno H, et al. Chemoprevention of azoxymethane-induced rat aberrant crypt foci by dietary zerumbone isolated from Zingiber zerumbet. Life Sci. 2001;69:1935-1945.
7. Murakami A, Takahashi M, Jiwajinda S, et al. Identification of zerumbone in Zingiber zerumbet Smith as a potent inhibitor of 12-O-tetradecanoylphorbol- 13-acetateYinduced Epstein-Barr virus activation. Biosci Biotechnol Biochem. 1999;63:1811-1812.
8. Matthes HWD, Luu B, Ourisson G. Cytotoxic components of Zingiber zerumbet, Curcuma zedoria, and C. domestica. Phytochemistry. 1980; 19:2643-2650.
9. Murakami A, Takhasih D, Kinoshita T, et al. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radicalgeneration, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha, beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis. 2002;23:795-802.
10. Ahmad B, Siddig I, Nirmala D, et al. The establishment and use of an in vivo animal model for cervical intra-epithelial neoplasia. Int J Cancer Res. 2008;4:61-70.
11. Mun KS, Cheah PL, Baharudin NB, et al. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver. Malays J Pathol. 2006;28:73-77.
12. Galanski M. Recent developments in the field of anticancer platinum complexes. Recent Patents Anticancer Drug Discov. 2006;1:285-295.
13. Kostova I. Platinum complexes as anticancer agents. Recent Patents Anticancer Drug Discov. 2006;1:1-22.
14. Malinge J-M, Giraud-Panis M-J, Leng M. Interstrand cross-links of cisplatin induce striking distortions in DNA. J Inorg Biochem. 1999; 77:23-29.
15. Richard DW, Richard JW, Keith NS, et al. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 2008;249: 184-193.
16. Lee RH, Song JM, Park MY, et al. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 2001;62:1013-1023.
17. Sheikh MS, Antinore MJ, Huang Y, et al. Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor1. Oncogene. 1998;17:2555-2563.
18. Wu C, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005;4:25.
19. Ajith TA, Nivitha V, Usha S. Zingiber officinale Roscoe alone and in combination with alpha-tocopherol protect the kidney against cisplatin-induced acute renal failure. Food Chem Toxicol. 2007;45:921-927.
20. Kuhad A, Tirkey N, Pilkhwal S, et al. 6-Gingerol prevents cisplatin-induced acute renal failure in rats. Biofactors. 2006; 26:189-200.
21. Kuhad A, Pilkhwal S, Sharma S, et al. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem. 2007;55:10150-10155.
22. Meng LH, Kong BH, Zhang YZ, et al. Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 2007;42:683-687.
23. Masters JR. HeLa cells 50 years on: the good, the bad, and the ugly. Nat Rev Cancer. 2002;2:315-319.
24. Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/Bcl-2 ratio. Cancer Cell Int. 2007;7:4.
25. Pan MH, Gao JH, Lai CS, et al. Antitumor activity of 3,5,4¶- trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog. 2008;47:184-196.
26. Park JS, Rhyu JW, Kim CJ, et al. Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in HPV-18 URR E6/E7 transgenic mice. Gynecol Oncol. 2003;89:360-368.
27. Goel MM, Mehrotra A, Singh U, et al. MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear. Diagn Cytopathol. 2005;33:15-19.
28. Pradhan B, Pradhan SB, Mital VP. Correlation of Pap smear findings with clinical findings and cervical biopsy. Kathmandu Univ Med J (KUMJ). 2007;5:461-467.
29. De S, Chakraborty J, Chakraborty RN, et al. Chemopreventive activity of quercetin during carcinogenesis in cervix uteri in mice. Phytother Res. 2000;14:347-351.
30. Markowska J. Tumor markers in cervical cancer. Ginekol Pol. 2007; 78:715-718.
31. Su JL, Lai KP, Chen CA, et al. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res. 2005;65:4827-4835.
32. Tjiong MY, van der Vange N, ten Kate FJW, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol Oncol. 1999;73:285-291.